What to watch in the biomedical space over the next five years
The pandemic has brought the spotlight onto the healthcare and biomedical sectors, driving unprecedented enthusiasm in the relatively unknown field of mRNA innovations, and bolstering growth in digital health. Yet, the silver lining has dulled investors’ sentiments post-COVID. Increasingly, investors have become more cautious against macroeconomic headwinds, and many are expecting a correction in company valuations across all sectors.
